The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Open accessAbstract
OBJECTIVE: To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab plus standard therapy compared with placebo plus standard therapy in active systemic lupus erythematosus (SLE). METHODS: In a phase III, multicenter, randomized, placebo-controlled trial, 819 antinuclear antibody-positive or anti-double-stranded DNA-positive SLE patients with scores ≥6 on the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the SLE Disease Activity Index (SLEDAI) were randomized in a 1:1:1 ratio to receive 1 mg/kg belimumab, 10 mg/kg belimumab, or placebo intravenously on days 0, 14, and 28 and then every 28 days for 72 weeks. The primary efficacy end point was the SLE Responder Index (SRI) response rate at week 52 (an SRI response was defined as a ≥4-point reduction in SELENA-SLEDAI score, no new British Isles Lupus Assessment Group [BILAG] A organ domain score and no more than 1 new BILAG B score, and no worsening in physician's global assessment score versus baseline). RESULTS: Belimumab at 10 mg/kg plus standard therapy met the primary efficacy end point, generating a significantly greater SRI response at week 52 compared with placebo (43.2% versus 33.5%; P = 0.017). The rate with 1 mg/kg belimumab was 40.6% (P = 0.089). Response rates at week 76 were 32.4%, 39.1%, and 38.5% with placebo, 1 mg/kg belimumab, and 10 mg/kg belimumab, respectively. In post hoc sensitivity analyses evaluating higher SELENA-SLEDAI score thresholds, 10 mg/kg belimumab achieved better discrimination at weeks 52 and 76. Risk of severe flares over 76 weeks (based on the modified SLE Flare Index) was reduced with 1 mg/kg belimumab (34%) (P = 0.023) and 10 mg/kg belimumab (23%) (P = 0.13). Serious and severe adverse events, including infections, laboratory abnormalities, malignancies, and deaths, were comparable across groups. CONCLUSION: Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074
Self-citationMortality in systemic lupus erythematosus
Bernatsky, S., Boivin, J. ‐., Joseph, L., Manzi, S., Ginzler, E., Gladman, D. D., Urowitz, M., Fortin, P. R., Petri, M., Barr, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21955 · Cited by 1,181
Self-citationCombined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri, M., Kim, M. Y., Kalunian, K. C., Grossman, J., Hahn, B. H., Sammaritano, L. R., Lockshin, M., Merrill, J. T., Belmont, H. M., Askanase, A. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051135 · Cited by 1,166
Self-citationBLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator
Moore, P. A., Belvedere, O., Orr, A., Pieri, K., LaFleur, D. W., Feng, P., Soppet, D., Charters, M., Gentz, R., Parmelee, D., et al. (1999) · Science · doi:10.1126/science.285.5425.260 · Cited by 1,144
D'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Cheema, G. S., Roschke, V., Hilbert, D. M., & Stohl, W. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1313::aid-art223>3.0.co;2-s · Cited by 802
Self-citationCutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus
Zhang, J., Roschke, V., Baker, K. P., Wang, Z., Alarcón, G. S., Fessler, B. J., Bastian, H., Kimberly, R. P., & Zhou, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.6 · Cited by 734
Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., Petri, M. A., Ginzler, E. M., Chatham, W. W., McCune, W. J., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24699 · Cited by 585
Self-citation
Cited by
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Self-citationHahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Self-citationKaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Self-citationTrial of Anifrolumab in Active Systemic Lupus Erythematosus
Morand, E. F., Furie, R., Tanaka, Y., Bruce, I. N., Askanase, A. D., Richez, C., Bae, S.-C., Brohawn, P. Z., Pineda, L., Berglind, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912196 · Cited by 1,379
Self-citationNew insights into the immunopathogenesis of systemic lupus erythematosus
Tsokos, G. C., Lo, M. S., Reis, P. C., & Sullivan, K. E. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.186 · Cited by 1,226
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, A., Müller, F., Mougiakakos, D., Böltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simon, D., Kleyer, A., Munoz, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,092
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001180 · Cited by 1,032
Self-citationAnders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Inflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Self-citationUpdate οn the diagnosis and management of systemic lupus erythematosus
Fanouriakis, A., Tziolos, N., Bertsias, G., & Boumpas, D. T. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218272 · Cited by 753
Lisnevskaia, L., Murphy, G., & Isenberg, D. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60128-8 · Cited by 752
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
van Vollenhoven, R. F., Mosca, M., Bertsias, G., Isenberg, D., Kuhn, A., Lerstrøm, K., Aringer, M., Bootsma, H., Boumpas, D., Bruce, I. N., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205139 · Cited by 740
Self-citationB cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Pathogenesis of autoimmune disease
Pisetsky, D. S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00720-1 · Cited by 649
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Self-citationNovel paradigms in systemic lupus erythematosus
Dörner, T., & Furie, R. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30546-x · Cited by 565
Self-citationType I Interferon in the Pathogenesis of Lupus
Crow, M. K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1002795 · Cited by 561
Furie, R. A., Morand, E. F., Bruce, I. N., Manzi, S., Kalunian, K. C., Vital, E. M., Lawrence Ford, T., Gupta, R., Hiepe, F., Santiago, M., et al. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30076-1 · Cited by 512
Self-citationThe TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
Dostert, C., Grusdat, M., Letellier, E., & Brenner, D. (2019) · Physiological Reviews · doi:10.1152/physrev.00045.2017 · Cited by 498
Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective
Moulton, V. R., Suarez-Fueyo, A., Meidan, E., Li, H., Mizui, M., & Tsokos, G. C. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.05.006 · Cited by 469
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
The BAFF/APRIL system in SLE pathogenesis
Vincent, F. B., Morand, E. F., Schneider, P., & Mackay, F. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.33 · Cited by 448
The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity
Vincent, F. B., Saulep-Easton, D., Figgett, W. A., Fairfax, K. A., & Mackay, F. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.04.003 · Cited by 445
Lee, S. J., Wolff, D., Kitko, C., Koreth, J., Inamoto, Y., Jagasia, M., Pidala, J., Olivieri, A., Martin, P. J., Przepiorka, D., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.02.025 · Cited by 431
Taming lupus-a new understanding of pathogenesis is leading to clinical advances
Liu, Z., & Davidson, A. (2012) · Nature Medicine · doi:10.1038/nm.2752 · Cited by 433
CAR T-cell therapy in autoimmune diseases
Schett, G., Mackensen, A., & Mougiakakos, D. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01126-1 · Cited by 430
Stohl, W., Schwarting, A., Okada, M., Scheinberg, M., Doria, A., Hammer, A. E., Kleoudis, C., Groark, J., Bass, D., Fox, N. L., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40049 · Cited by 420
Self-citationStohl, W., Hiepe, F., Latinis, K. M., Thomas, M., Scheinberg, M. A., Clarke, A., Aranow, C., Wellborne, F. R., Abud‐Mendoza, C., Hough, D. R., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34400 · Cited by 418
Self-citationvan Vollenhoven, R. F., Petri, M. A., Cervera, R., Roth, D. A., Ji, B. N., Kleoudis, C. S., Zhong, Z. J., & Freimuth, W. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200937 · Cited by 411
Self-citationManzi, S., Sánchez-Guerrero, J., Merrill, J. T., Furie, R., Gladman, D., Navarra, S. V., Ginzler, E. M., D'Cruz, D. P., Doria, A., Cooper, S., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200831 · Cited by 411
Self-citationBAFF and BAFF-Receptor in B Cell Selection and Survival
Smulski, C. R., & Eibel, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02285 · Cited by 372
Gordon, C., Amissah-Arthur, M.-B., Gayed, M., Brown, S., Bruce, I. N., D’Cruz, D., Empson, B., Griffiths, B., Jayne, D., Khamashta, M., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/kex286 · Cited by 365
The pathogenesis of systemic lupus erythematosus—an update
Choi, J., Kim, S. T., & Craft, J. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.10.004 · Cited by 360
Danza, A., & Ruiz-Irastorza, G. (2013) · Lupus · doi:10.1177/0961203313493032 · Cited by 359
Kalunian, K. C., Merrill, J. T., Maciuca, R., McBride, J. M., Townsend, M. J., Wei, X., Davis, J. C., & Kennedy, W. P. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206090 · Cited by 340
Self-citationWallace, D. J., Kalunian, K., Petri, M. A., Strand, V., Houssiau, F. A., Pike, M., Kilgallen, B., Bongardt, S., Barry, A., Kelley, L., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202760 · Cited by 337
Self-citationMariette, X., Seror, R., Quartuccio, L., Baron, G., Salvin, S., Fabris, M., Desmoulins, F., Nocturne, G., Ravaud, P., & De Vita, S. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203991 · Cited by 329
Seror, R., Bootsma, H., Saraux, A., Bowman, S. J., Theander, E., Brun, J. G., Baron, G., Le Guern, V., Devauchelle-Pensec, V., Ramos-Casals, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206008 · Cited by 316
Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C. P., Wofsy, D., Babini, A., Lazaro, M., Lucero, E., Merono, C., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205067 · Cited by 306
Self-citationZhang, F., Bae, S.-C., Bass, D., Chu, M., Egginton, S., Gordon, D., Roth, D. A., Zheng, J., & Tanaka, Y. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211631 · Cited by 305
New insights into the role of antinuclear antibodies in systemic lupus erythematosus
Pisetsky, D. S., & Lipsky, P. E. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0480-7 · Cited by 303
Targeting B cells and plasma cells in autoimmune diseases
Hofmann, K., Clauder, A.-K., & Manz, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00835 · Cited by 294
Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases
Croft, M., & Siegel, R. M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.22 · Cited by 288
Anti-DNA antibodies–quintessential biomarkers of SLE
Pisetsky, D. S. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.151 · Cited by 267
Morand, E., Pike, M., Merrill, J. T., van Vollenhoven, R., Werth, V. P., Hobar, C., Delev, N., Shah, V., Sharkey, B., Wegman, T., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42391 · Cited by 266
Self-citationDooley, M., Houssiau, F., Aranow, C., D’Cruz, D., Askanase, A., Roth, D., Zhong, Z., Cooper, S., Freimuth, W., & Ginzler, E. (2013) · Lupus · doi:10.1177/0961203312465781 · Cited by 265
Self-citationSystematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Approaches for estimating minimal clinically important differences in systemic lupus erythematosus
Rai, S. K., Yazdany, J., Fortin, P. R., & Aviña-Zubieta, J. A. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0658-6 · Cited by 251
Clowse, M. E. B., Wallace, D. J., Furie, R. A., Petri, M. A., Pike, M. C., Leszczyński, P., Neuwelt, C. M., Hobbs, K., Keiserman, M., Duca, L., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39856 · Cited by 235
“Even in these trials, there was a higher than expected placebo response, and one of the trials only just marginally showed a significant difference in favor of belimumab (22,23).”
BackgroundResultSelf-citationSystemic lupus erythematosus diagnosis and management
Thong, B., & Olsen, N. J. (2016) · Rheumatology · doi:10.1093/rheumatology/kew401 · Cited by 120
Immunomodulators in SLE: Clinical evidence and immunologic actions
Durcan, L., & Petri, M. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.010 · Cited by 92
Self-citationPego‐Reigosa, J. M., Cobo‐Ibáñez, T., Calvo‐Alén, J., Loza‐Santamaría, E., Rahman, A., Muñoz‐Fernández, S., & Rúa‐Figueroa, Í. (2013) · Arthritis Care & Research · doi:10.1002/acr.22035 · Cited by 74
Bentow, C., Lakos, G., Martis, P., Wahl, E., Garcia, M., Viñas, O., Espinosa, G., Cervera, R., Sjöwall, C., Carmona-Fernandes, D., et al. (2016) · Lupus · doi:10.1177/0961203316640917 · Cited by 37
Self-citationArriens, C., Aberle, T., Carthen, F., Kamp, S., Thanou, A., Chakravarty, E., James, J. A., Merrill, J. T., & Ogunsanya, M. E. (2020) · Lupus Science & Medicine · doi:10.1136/lupus-2019-000360 · Cited by 19
Self-citation
Metadata
- Authors
- Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., Stohl, W., Ginzler, E. M., Hough, D. R., Zhong, Z. J., Freimuth, W., van Vollenhoven, R. F., & BLISS-76 Study Group
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2011-11-29
- Volume
- 63
- Issue
- 12
- Pages
- 3918-3930
- ISSN
- 0004-3591 (ISSN-L)
- OpenAlex
- W2136149088
- Cited by
- 1,683
- References
- 30
- FWCI
- 59.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.